Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”

NFR CEO Shay Says Yes on Health Care, No on Border Tax
46:18 - Matthew Shay, chief executive officer at National Retail Federation, talks about his support of the American Health Care Act and explains why a border adjustment tax will hurt consumers and the U.S. economy. He speaks on "Bloomberg Daybreak: Americas." (Source: Bloomberg)
  • Barclays Analyst Sees Year-End S&P 500 at 2,525
  • Peterson's Kirkegeaard Says Global Terror Fight Continues
  • BlackRock's Bisat Sees EM in Sweet Spot Right Now